Physician profile
John Das
NPI 1053052290
$3,951.24
in general payments reported to CMS, 2019-2025
25 companies · $1,473 in 2025
The $1,473 reported for 2025 was more than what 91% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $179 · 2023: $461 · 2024: $1,838 · 2025: $1,473.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,582 · Education: $190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,582.12 |
| Education | $189.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $634.49 | 2023-2025 | Arexvy, Nucala, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $533.10 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $514.34 | 2022-2025 | Ofev, Jardiance |
| Inspire Medical Systems, INC. | $434.17 | 2024-2025 | Inspire |
| Abbott Laboratories | $236.66 | 2024-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Janssen Pharmaceuticals, INC | $224.93 | 2024 | Xarelto |
| Phadia US INC. | $186.76 | 2025 | Immunocap |
| Lilly USA, LLC | $180.86 | 2024-2025 | Mounjaro, Zepbound |
| Pfizer INC. | $169.37 | 2022-2025 | |
| Harmony Biosciences LLC | $165.57 | 2025 | |
| Amgen INC. | $95.06 | 2025 | Repatha |
| Jazz Pharmaceuticals INC. | $90.00 | 2025 | |
| Abbvie INC. | $86.19 | 2024-2025 | |
| Grifols USA, LLC | $70.84 | 2024 | Prolastin-C Liquid |
| Novo Nordisk INC | $67.65 | 2022-2025 | Ozempic, Wegovy |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avadel Cns Pharmaceuticals, LLC | $67.12 | 2025 | Lumryz |
| Ucb, INC. | $29.67 | 2025 | Bimzelx |
| Tg Therapeutics, INC. | $27.78 | 2025 | |
| Sumitomo Pharma America, INC. | $25.31 | 2024 | Gemtesa |
| Lundbeck LLC | $23.89 | 2025 | Vyepti |
| Xeris Pharmaceuticals, INC. | $19.99 | 2023 | Gvoke Hypopen |
| Eisai INC. | $19.03 | 2024 | |
| Novartis Pharmaceuticals Corporation | $18.39 | 2025 | |
| Merck Sharp & Dohme LLC | $15.92 | 2025 | Capvaxive, Gardasil 9 |
| Corcept Therapeutics | $14.15 | 2024 | Korlym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Das listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.